|
KMID : 0624620220550120595
|
|
BMB Reports
2022 Volume.55 No. 12 p.595 ~ p.601
|
|
|
The role of EZH1 and EZH2 in development and cancer
|
|
Lee Soo-Hyun
Li Yingying
Kim Han-Byeol
Eum Seoung-Hyun
Park Kyu-Min
Lee Chul-Hwan
|
|
|
Abstract
|
|
|
|
Polycomb Repressive Complex 2 (PRC2) exhibits key roles in mammalian development through its temporospatial repression of gene expression. EZH1 or EZH2 is the catalytic subunit of PRC2 that mediates the mono-, di- and tri-methylation of histone H3 lysine 27 (H3K27me1/2/3), H3K27me2/me3 being a hallmark of facultative heterochromatin. PRC2 is a chromatin-modifying enzyme that is recruited to a limited number of “nucleation sites”, spreads H3K27 methylation and fosters chromatin compaction. EZH1 and EZH2 exhibit differences in their expression patterns, levels of histone methyltransferase activity (HMT) in the context of PRC2, and DNA/nucleosome binding activity. This suggests that their roles in heterochromatin formation are disparate. Dysregulation of PRC2 activity leads to aberrant gene expression and is implicated in cancer and developmental diseases. In this review, we discuss the distinct function of PRC2/EZH1 and PRC2/EZH2 in the early and late developmental stages. We then discuss the cancers associated with PRC2/EZH1 and PRC2/EZH2.
|
|
|
KEYWORD
|
|
|
Cancer, Development, Epigenetics, EZH1/2, Heterochromatin, PRC2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|